Drugs / K777
K777
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06146374 | Apr → Jul 2024 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04843787 | Nov 2023 → Jun 2024 | COVID-19 | Kenneth Krantz, MD, PhD | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K777 | “SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2.” NCT06146374 ↗ |
| Known as | APC-3316 | ChEMBL registry synonym — accepted as the source's own label CHEMBL91704 ↗ |
| Known as | CRA-3316 | ChEMBL registry synonym — accepted as the source's own label CHEMBL91704 ↗ |
| Known as | K-1177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL91704 ↗ |
| Known as | K-11777 | ChEMBL registry synonym — accepted as the source's own label CHEMBL91704 ↗ |
| Known as | SLV213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06146374 ↗ |
| Action | Inhibit | “a vinyl sulfone cysteine protease inhibitor” NCT06146374 ↗ |
| Modality | Small molecule | “SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid” NCT06146374 ↗ |
| Route | Oral | “SLV213 oral capsule (200mg) BID” NCT04843787 ↗ |